Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:AMGN
Date1/1983
Raised
Post IPO Valuation

General Information

Websiteamgen.com
Twitter@amgen
CategoryBioTech
Phone+1 805-447-1000
Emailinvestor.relation...
Employees17,800
Founded1985
DescriptionBiotechnology company

Offices

HQ
One Amgen Center Drive
Thousand Oaks, CA, 91320-1799
USA

People

SVP
SVP, Global Marketing and Commercial Development
SVP, U.S. Commercial Operations
SVP, Corporate Affairs
SVP and CIO
SVP, Human Resources
SVP, Global Value and Access
SVP and Chief Compliance Officer
Show All People

Acquisitions

Total$12.6B
Onyx Pharmaceuticals, 8/2013 $10.5B
KAI Pharmaceuticals, 4/2012 $315M
Micromet, 1/2012 $1.16M
BioVex, 1/2011 $1B
Avidia, 10/2008 $380M
Ilypsa, 6/2007 $420M

Investments

Funding

TOTAL $175M
FUNDING TOTAL $175M
Partial Close, 3/2012
$175M

Service Providers

Legal

Tags

Amgen

Amgen Inc. - The Group’s principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation.

The Group’s key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis.

Recent Milestones

Videos

Screenshots

Amgen screenshot
Above: Amgen Screenshot -- #1
Uploaded: 9/16/09
Amgen screenshot
Above: Homepage
Uploaded: 4/11/14

Stock Price

Sources

  1. Amgen Said to Be Near Deal to Buy Onyx for $10.5 Billion (dealbook.nytimes.com) [edit]
  2. UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout (fiercebiotech.com) [edit]
  3. Amgen to Acquire Micromet (amgen.com) [edit]
  4. BioVex to be acquired by Amgen for up to $1 billion (masshightech.com) [edit]
  5. Amgen to buy inflammation drug co. Avidia for up to $380M (deals.venturebeat.com) [edit]
  6. Amgen buys kidney-disease biotech Ilypsa for $420M (venturebeat.com) [edit]
  7. Sutro Biopharma Secures $26M in Series D Financing (finsmes.com) [edit]
  8. Opsona Therapeutics Raises €3M Series C Equity Financing (finsmes.com) [edit]
  9. Opsona Therapeutics Raises €33M in Series C Financing (finsmes.com) [edit]
  10. Theraclone Sciences Closes $14M in Series B and Debt Financing (finsmes.com) [edit]
  11. Gamida Cell Closes $10m Series E Financing (finsmes.com) [edit]
  12. Sutro Closes $16.5 Million Second Tranche of Series C Financing (finance.yahoo.com) [edit]
  13. MiRagen Therapeutics Completes $20M Series B Financing (finsmes.com) [edit]
  14. Ardelyx, Inc. Closes $30M Series B Financing (ardelyx.com) [edit]
  15. Oncofactor, Inc.: Series A $2.1M (onbiovc.com) [edit]
  16. Acylin Therapeutics, Inc.: Series A $4.4M (onbiovc.com) [edit]
  17. Sutro Biopharma Secures $36.5M in Series C Financing (finsmes.com) [edit]
  18. DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding (finsmes.com) [edit]
  19. TetraLogic nabs $32M round for lead cancer therapy Read more: TetraLogic nabs $32M round for lead cancer therapy (fiercebiotech.com) [edit]
  20. Calistoga Pharmaceuticals Raises $40 Million in Series C Financing (calistogapharma.com) [edit]
  21. Theraclone Raises $1.5M (xconomy.com) [edit]
  22. SEC D/A (sec.gov) [edit]
  23. Epizyme pulls in $32M in VC capital, new investors (fiercebiotech.com) [edit]
  24. biospace.com [edit]
  25. Capital Report Index [edit]
  26. InteKrin raises $18.5M for continued work on diabetes drug (venturebeat.com) [edit]
  27. Allozyne, Inc., Closes $30 Million Series B Financing (allbusiness.com) [edit]
  28. Argolyn Bioscience Raises $15.8 Million Round of Financing (salesandmarketingnetwork.com) [edit]
  29. Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of a $21 million Series A financing (calistogapharma.com) [edit]
  30. EDGAR [edit]
  31. VLST Corporation Raises $55 Million (vlstcorp.com) [edit]
  32. Viron Therapeutics raises US $20 million (vironinc.com) [edit]
  33. AVIDIA RAISES $43.8 MILLION TO ADVANCE NEW CLASS OF PHARMACEUTICALS (freshnews.com) [edit]
  34. Allozyne Inc. Raises $3.5 Million in Series A Funding (goodwinprocter.com) [edit]
  35. PTC THERAPEUTICS RAISES $26.6 MILLION IN PRIVATE PLACEMENT FINANCING (ptct.client.shareholder.com) [edit]
  36. AVIDIA ADVANCING LEAD PRODUCT THROUGH $28.5M SERIES B ROUND. (thefreelibrary.com) [edit]
  37. SEC (sec.gov) [edit]
  38. Amgen pays Nektar $50M for polymer (fiercebiotech.com) [edit]
    BioVex to be acquired by Amgen for up to $1 billion (masshightech.com) [edit]
    Amgen Invests $25 Million to Expand Cytokinetics Agreement (burrillreport.com) [edit]
Edit This Page
Last Edited 4/11/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy